Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009

[1]  G. Giaccone,et al.  SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Song,et al.  Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  K. Krejcy,et al.  Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Miller,et al.  A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Herbst,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Michael Thomas,et al.  Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Cappuzzo,et al.  Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. , 2009, Journal of Clinical Oncology.

[8]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[9]  Martin Marciniak,et al.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  David J Sugarbaker,et al.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Torri,et al.  A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S. , 2008 .

[13]  R. Ramlau,et al.  Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study , 2008 .

[14]  R. Herbst,et al.  Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Herbst,et al.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Crowley,et al.  S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial , 2007 .

[17]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[18]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[19]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[20]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[21]  M. Parmar,et al.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[24]  G. Giaccone,et al.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. , 2003, Journal of the National Cancer Institute.